CRISPR-Cas9 has changed the field of genome engineering. But, its use as a gene modifying software is limited by off-target outcomes and the prospect of lasting DNA damage. To deal with these limitations, analysts are suffering from a revised version of Cas9, known as dCas9. Unlike Cas9, which can cut DNA, dCas9 is catalytically inactive and alternatively binds to certain DNA sequences. This...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian